Publication | Closed Access

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

Neurodegenerative DiseasesAlzheimer's DiseaseMedicineBiomarkersNeurochemical BiomarkersNeurologyNeuroscienceBiomarker FindingsPhase IiaModifying TherapyPharmacologyAging-associated DiseaseTreatment